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Abstract: Children and adolescents with Tourette syndrome may suffer from comorbid psychological
and behavioral difficulties, primarily Attention-Deficit Hyperactivity Disorder-related manifestations
including impulsive, aggressive, and disruptive behavior, and Obsessive-Compulsive Disorder-
related disturbances. Often, such additional problems represent the major cause of disability, re-
quiring their prioritization above the tic symptomatology. Here, we present six cases of children
and adolescents with treatment-resistant Tourette syndrome aged 11–17 years, whose symptoms,
especially the non-tic symptoms such as aggressive behavior and obsessive symptoms, failed to
respond adequately to at least two different antipsychotics and, where deemed appropriate, to a
combination with a medication with a different therapeutic indication or chemical class (e.g., antide-
pressant or anticonvulsant). Such symptomatic manifestations were significantly reduced by the time
of the subsequent control visit planned 30 days later, by using lurasidone as an add-on therapy to
risperidone or aripiprazole (all p ≤ 0.009). No significant neuromotor or metabolic side effects were
reported in all cases in a follow-up period ranging from 4 months to 6 months, supporting the stability
of the observed clinical improvement. While still investigational, the preliminary evidence presented
here gives reason to hope that lurasidone could possibly be an effective option in Tourette syndrome,
warranting further investigation of its potential benefits in neurodevelopmental conditions.
Keywords: treatment resistant Tourette disorder; psychopharmacological treatment; aripiprazole;
risperidone; case report
1. Introduction
Beyond pathognomonic motor and vocal tics, children and adolescents with Tourette
syndrome (TS) suffer from comorbid psychological and behavioral difficulties, primar-
ily Attention-Deficit Hyperactivity Disorder-related manifestations including impulsive,
aggressive, and disruptive behavior, and Obsessive-Compulsive Disorder-related distur-
bances. Other symptoms less commonly reported are anxiety, mood swings, and person-
ality alterations. Such additional problems often represent the major cause of disability,
requiring their prioritization above the tic symptomatology [1].
TS treatment can be conceptualized in three phases. First, psychosocial interventions
(e.g., psychoeducation and social support) should be offered to all TS individuals and
their families. Second, depending on the symptom severity and related impairment,
active interventions can be pursued, including behavioral and pharmacological therapies.
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Antipsychotics are the most commonly used medications, followed by alpha agonists and
other compounds including anticonvulsants, muscle relaxant agents, cannabis-derived
formulations, and immunoglobulins. Third, when TS is refractory to both behavioral and
pharmacological treatments, individuals may be eligible for neuromodulation interventions.
However, such interventions can be invasive and less feasible in common clinical settings,
and there is uncertainty regarding the selection of patients and target of intervention [2].
Most of the evidence regarding the efficacy of antipsychotic drugs in TS comes from
studies with haloperidol, pimozide, risperidone, and aripiprazole. More limited evidence
also supports the use of ziprasidone, tiapride, and metoclopramide. While risperidone
and aripiprazole are Food and Drug Administration (FDA)-approved medications for
behavioral disturbances other than tics in children and adolescents, there is no solid
evidence to establish superiority of one medication relative to another and side effects have
been reported for all tested medications. Importantly, because of the phenotypic variability,
no antipsychotic has proven effective for all patients with TS [3]. The last decade has seen
the approval of new antipsychotic drugs, one of which is lurasidone. Unique to lurasidone
is a potent antagonism at the serotonin 5-HT7 receptor, which, coupled with 5-HT1A
partial agonism, could potentially be associated with additional cognitive-enhancing and
antidepressant effects. In addition, lurasidone shows low affinity for the M1, H1, 5-HT2C,
and α1 receptors, suggesting a low liability to cause peripheral and central anticholinergic
side effects, somnolence, weight gain, and hypotension [4].
Evidence indicates that antipsychotic polypharmacy (APP), i.e., the co-prescription of
more than one antipsychotic medication for an individual patient, is a relatively frequent
and consistent practice in adults, with a prevalence of up to 50% in clinical settings devoted
to the treatment of severe psychosis [5]. While current treatment guidelines state that an-
tipsychotic monotherapy (APM) should be preferred to APP, based on high-quality studies
of the acute-phase treatment, recent evidence from a 20-year follow-up study conducted
among a nationwide cohort of 62,250 psychosis patients indicates that certain APP may
be superior to APM for maintenance treatment, indicating the need for a modification of
categorical recommendations discouraging APP in the maintenance treatment of severe
psychosis [6]. A systematic review of youth studies spanning 15 years found that APP
is also common in children and adolescents, especially with Attention-Deficit Hyperac-
tivity Disorder (ADHD) and oppositional defiant disorder (ODD), with a prevalence of
APP among antipsychotic-treated youth of about 10% (6% in child studies and 12% in
adolescent studies) [7]. Furthermore, APP has been shown to be used to control aggressive
and disruptive behavior in acute pediatric settings, especially in the context of intellectual
disability and developmental disorders [8].
Using two or more psychopharmacological medications may be more effective than
monotherapy for symptom control, especially if the mechanisms of action are complemen-
tary (e.g., antipsychotic-antidepressant or antipsychotic-anticonvulsant combination) [9,10].
Instead, it may be argued that the concomitant use of two or more pharmacologically
similar antipsychotics lacks scientific rationale, also exposing the patient to the risk of
pharmacokinetic interactions that may have important implications for drug overdosing
and adverse neuromotor or metabolic side effects, and thus raising particular concerns
for youth populations [11]. Nevertheless, in the real-world clinical experience, APP may
sometimes be the last or only feasible option to obtain greater therapeutic response than
has been achieved with APM.
We investigated the use of lurasidone as an augmentation treatment of risperidone/
aripiprazole in six consecutive cases of children and adolescents with treatment-resistant
TS. The eligibility criteria included the presence of symptoms, especially non-tic symptoms
such as aggressive behavior and obsessive symptoms, that failed to respond adequately
to at least two different antipsychotics and, when deemed appropriate, to respond to a
combination with a medication with a different therapeutic indication or chemical class
(e.g., antidepressant or anticonvulsant).
Children 2021, 8, 121 3 of 13
2. Patient Information
As expected in the context of a neurodevelopmental condition [12,13], some of the TS
patients (age range, 11–17 years) presented with additional neurodevelopmental symp-
tomatology (e.g., autistic traits, hyperactivity features or borderline cognitive functioning).
However, the severity of the neuropsychiatric symptoms was not such as to fulfill the
criteria set by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5) for another neurodevelopmental disorder (e.g., autism spectrum disorder, ADHD,
or intellectual disability). Nevertheless, the associated psychopathology certainly con-
tributed to making the clinical presentation more complex, with significant implications
for treatment response [14], as well as management, overall outcome, and quality of life of
patients with such type of TS [15].
According to clinical judgement, reasons for avoiding the administration of medica-
tions other than the ones prescribed were the following: (i) suicide risk and/or elevated
aggressiveness (e.g., selective serotonin reuptake inhibitors, SSRI) and (ii) poor compliance
to treatments requiring strict monitoring (e.g., clozapine or lithium). As an option, APP
was extensively discussed with patients’ families in terms of potential benefits and risks,
and it was agreed to proceed in the context of individual trials including close monitoring
of clinical response, adverse effects, and physical health by medical examinations and
blood tests. Notably, all of the patients were also receiving psychological treatment during
the observation period, even though we could not formally assess the effect of such an
intervention.
Table 1 reports medical and family history of the patients as well as any relevant past
pharmacological interventions and outcomes. Every effort was made to conduct the most
accurate possible medication reconciliation, comprehensively determining the reasons for
psychopharmacological treatment prescriptions (e.g., tics, aggressiveness, and obsessive
symptoms); however, such process was not always possible due to the lower quality of
certain medical records.
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Table 1. Flow chart of pharmacological intervention up to lurasidone add-on therapy to risperidone or aripiprazole in six children/adolescents with Tourette syndrome.


















Aripiprazole (??) Optimal Suboptimal Suboptimal
Aripiprazole (up to 10 Mg/D,
11 months) + fluvoxamine (??,
11 months) [11 years, 7 months]
Optimal Suboptimal Suboptimal
Aripiprazole (10 Mg/D,
11 months) [12 years, 6 months] Optimal Suboptimal Suboptimal
Aripiprazole (10 Mg/D,
3 months) + olanzapine (up to
7.5 Mg/D, 3 months) [13 years,
5 months]
Optimal Suboptimal Suboptimal
Olanzapine (10 Mg/D, 4 months)
[13 years, 8 months] Optimal Suboptimal Optimal
Olanzapine (10 Mg/D, 9 months)
+ topiramate (50 Mg/D,
9 months) [14 years]
Suboptimal Suboptimal Suboptimal
Olanzapine (10 Mg/D,
12 months) [14 years, 9 months] Suboptimal Suboptimal Suboptimal
Aripiprazole (up to 15 Mg/D,
12 months) [15 years, 9 months] Optimal Suboptimal Suboptimal
Aripiprazole (15 Mg/D, 1 month)
+ lurasidone (18.5 Mg/D,
1 month) [16 years, 9 months]
Optimal Optimal Suboptimal
Aripiprazole (15 Mg/D, ongoing)
+ lurasidone (37 Mg/D, ongoing) Optimal Optimal Optimal
















Risperidone (up 0.75 Mg/D,
19 months) [6 years, 7 months] Suboptimal Optimal Suboptimal
Risperidone (1 Mg/D, 7 months)
+ aripiprazole (up to 6 Mg/D,
7 months) [8 years, 2 months]
Optimal Suboptimal Suboptimal
Risperidone (1 Mg/D, 12
months) + aripiprazole (6 Mg/D,
12 months) + methylphenidate
(10 Mg/D, 12 months) [8 years,
9 months]
Suboptimal Optimal Suboptimal
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Risperidone (up to 4 Mg/D,
17 months) + aripiprazole (up to
15 Mg/D, 17 months) +
methylphenidate (10 Mg/D,
17 months) + IVIG (15 g,
17 months) [9 years, 9 months]
Optimal Suboptimal Suboptimal
Risperidone (4 Mg/D, 4 months)
+ aripiprazole (15 Mg/D,
4 months) + clomipramine (up to
20 Mg/D, 4 months) + VPA (up
to 600 Mg/D, 4 months) + IVIG
(15 g, 4 months) [11 years,
2 months]
Optimal Suboptimal Suboptimal
Risperidone (4 Mg/D, 4 months)
+ aripiprazole (15 Mg/D,
4 months) + fluvoxamine (up to
100 Mg/D, 4 months) + VPA
(600 Mg/D, 4 months) + IVIG
(15 g, 4 months) [11 years,
6 months]
Optimal Suboptimal Suboptimal
Risperidone (4 Mg/D, 3 months)
+ aripiprazole (15 Mg/D,
3 months) + levomepromazine
(up to 100 Mg/D, 3 months) +
fluvoxamine (100 Mg/D,
3 months) + VPA (600 Mg/D,
3 months) + IVIG (15 g, 3
months) [11 years, 10 months]
Optimal Suboptimal Suboptimal
Risperidone (4 Mg/D, ongoing) +
lurasidone (up to 74 Mg/D,
ongoing) + VPA (to 600 Mg/D,
ongoing) + IVIG (15 g, ongoing)
Optimal Optimal Optimal
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specified (??, ??) Optimal Suboptimal Suboptimal
Risperidone (up to 5 Mg/D, at
least 11 months) [10 years,
6 months]
Optimal Suboptimal Suboptimal
Risperidone (5 Mg/D, 2 months)
+ lurasidone (up to 74 Mg/D,
2 months) [11 years, 5 months]
Optimal Suboptimal Optimal
Risperidone (5 Mg/D, ongoing) +
lurasidone (up to 148 Mg/D,
ongoing)
Optimal Optimal Optimal
Child 4 17 Male ?? No No No Aripiprazole (??, ??) Optimal Suboptimal Suboptimal
Aripiprazole (??, ??) +
ziprasidone (??, ??) Optimal Suboptimal Suboptimal
Aripiprazole (up to 8 Mg/D, ??)




8 months) + haloperidol
(1.5 Mg/D, 8 months) [16 years,
9 months]
Optimal Suboptimal Suboptimal
Aripiprazole (up to 24 Mg/D,
1 month) + haloperidol (up to
3 Mg/D, 1 month) + lithium
sulphate PR (166 Mg/D,
1 month) [17 years, 5 months]
Optimal Suboptimal Suboptimal
Haloperidol (3 Mg/D, 20 days *)
+ lurasidone (74 Mg/D, 20 days)
+ lithium sulphate PR (166 Mg/D,
20 days) [17 years, 6 months]
Optimal Optimal Optimal
Aripiprazole (up to 30 Mg/D,
ongoing) + lurasidone (74 Mg/D,
ongoing) + lithium sulphate PR
(166 Mg/D, ongoing)
Optimal Optimal Optimal
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mood **) Yes (Diabetes)
Aripiprazole (10 Mg/D,
10 months) [11 years, 1 month] Suboptimal Optimal Suboptimal
Aripiprazole (10 Mg/D,
2 months) + risperidone
(4 Mg/D, 2 months) [11 years,
11 months]
Suboptimal Optimal Suboptimal
Aripiprazole (10 Mg/D, ongoing)
+ lurasidone (37 Mg/D, ongoing) Suboptimal Optimal Optimal










specified (??, ??) Optimal Suboptimal Suboptimal
Risperidone (6 Mg/D, 7 months)
[11 years, 7 months] Optimal Suboptimal Suboptimal
Aripiprazole (7 Mg/D, 7 months)
[12 years, 2 months] Optimal Suboptimal Suboptimal
Aripiprazole (up to 10 Mg/D,
8 months) + mirtazapine
(1 Mg/D, 8 months) [12 years,
9 months]
Optimal Suboptimal Suboptimal
Aripiprazole (10 Mg/D, 1 month)
+ lurasidone (74 Mg/D, 1 month)
[13 years, 5 months]
Optimal Optimal Suboptimal
Aripiprazole (10 Mg/D, ongoing)
+ lurasidone (111 Mg/D,
ongoing)
Optimal Optimal Optimal
Mg/D, milligrams per Day; OCD, obsessive compulsive disorder; GERD, gastroesophageal reflux disease; IVIG, intravenous immunoglobulin; VPA, valproic acid; ??, unknown; PR, prolonged release; *
discontinued due to reported sedation; ** depressive symptoms were improved by lurasidone; Optimal, clinical impression of symptom improvement >50%; Suboptimal, clinical impression of symptom
improvement <50%.
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3. Clinical Findings
After failure to control aggressive behavior or obsessive symptoms with other single
or combined agents, such symptomatic manifestations were regulated by the time of the
subsequent control visit planned 30 days later, by using lurasidone as an add-on therapy to
risperidone or aripiprazole. The following information is noteworthy: (i) Before the add-on
therapy with lurasidone, children themselves and their parents considered the additional
symptomatic manifestations unacceptable. (ii) In one case only, tics were sub-optimally
controlled with the ongoing treatment and lurasidone add-on appeared to be less beneficial
in reducing tics, while reducing aggressive behavior and obsessive symptoms. (iii) In
the same case, lurasidone also improved depressive symptoms which were present in
comorbidity. (iv) In another case, lurasidone was firstly tried as an add-on therapy to
haloperidol, which was already in place; however, despite reducing aggressive behavior
and obsessive symptoms, the combination was poorly tolerated due to reported sedation.
All clinical data, including therapeutic interventions’ dosage and duration, are organized
as a timeline in Table 1.
4. Follow-Up and Outcomes
Two physicians independently performed the following: (a) the Clinical Global Im-
pression (CGI) in order to assess (i) severity of illness (before lurasidone add-on, 5.83 ± 1.17
(Mean, M ± Standard Deviation, SD); after lurasidone add-on, 3.17 ± 0.75; t = 8.0, p < 0.001),
(ii) global improvement, and (iii) treatment efficacy [16] (Table 2); (b) the Modified Overt
Aggression Scale (MOAS) in order to assess (i) verbal aggression, (ii) aggression against
property, (iii) auto-aggression, and (iv) physical aggression (weighted sum before lurasi-
done add-on, 12.50 ± 6.32; weighted sum after lurasidone add-on, 5.83 ± 2.64; t = 4.1,
p = 0.009) [17] (Table 3); and (c) the Children’s Yale-Brown Obsessive Compulsive Scale
(CY-BOCS Symptom Checklist) in order to assess severity of (i) obsessions and (ii) compul-
sions (total score before lurasidone add-on, 22.00 ± 2.97; total score after lurasidone add-on,
15.50 ± 1.05; t = 7.1, p < 0.001) [18] (Table 4). In the rare instances of discrepant attribution,
consensus was reached through discussion with a third senior clinical researcher. Symptom
improvement as experienced by children’s parents was also collected from a narrative
perspective. Quotes were extracted by medical records or parents’ written communications
(Table 5).



















Child 3 7 4 2 Marked None




Child 5 4 2 2 Moderate None
Child 6 7 3 1 Marked None
CGI-S, CGI-Severity of illness; CGI-I, CGI-Global Improvement; CGI-E, CGI-Efficacy Index.
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Table 3. The Modified Overt Aggression Scale (MOAS).
Patient Current Treatment VA AAP AA PA Weighted Sum
Child 1
Before lurasidone 3 0 2 2 17
Lurasidone 18.5 Mg/D 2 0 1 1 9
Lurasidone 37 Mg/D 1 0 1 1 8
Child 2
Before lurasidone 1 2 0 2 13
Lurasidone 74 Mg/D 0 1 0 1 6
Child 3
Before lurasidone 1 0 2 3 19
Lurasidone 111 Mg/D 0 0 2 2 14
Lurasidone 148 Mg/D 0 0 1 1 7
Child 4
Before lurasidone 0 3 0 2 14
Lurasidone 74 Mg/D 0 2 0 1 8
Child 5
Before lurasidone 1 0 0 0 1
Lurasidone 37 Mg/D 1 0 0 0 1
Child 6
Before lurasidone 3 0 0 2 11
Lurasidone 74 Mg/D 1 0 0 2 9
Lurasidone 111 Mg/D 1 0 0 1 5
VA, verbal aggression; AAP, aggression against property; AA, auto-aggression; PA, physical aggression; Weighted Sum = (VAx1) + (AAPx2)
+ (AAx3) + (PAx4).
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Before Severe Moderate Mild Mild Little 10 Severe Severe Mild Mild Little 11 Moderate (21)
18.5 Mg/D Moderate Moderate Mild Mild Moderate 8 Moderate Moderate Mild Mild Moderate 8 Moderate (16)
37 Mg/D Mild Moderate Mild Mild Moderate 7 Mild Moderate Mild Mild Moderate 7 Mild (14)
Child 2
Before Severe Severe Mild Mild Little 11 Moderate Moderate Mild Mild Moderate 8 Moderate (19)
74 Mg/D Moderate Moderate Mild Mild Moderate 8 Mild Moderate Mild Mild Moderate 7 Mild (15)
Child 3
Before Severe Severe Moderate Moderate Little 13 Severe Severe Severe Moderate Little 14 Severe (27)
111 Mg/D Moderate Moderate Moderate Moderate Moderate 10 Moderate Moderate Moderate Moderate Moderate 10 Moderate (20)
148 Mg/D Moderate Moderate Mild Mild Moderate 8 Moderate Moderate Mild Moderate Moderate 9 Moderate (17)
Child 4
Before Moderate Moderate Moderate Mild Moderate 9 Severe Severe Moderate Mild Little 12 Moderate (21)
74 Mg/D Moderate Moderate Mild Mild Moderate 8 Moderate Moderate Mild Mild Moderate 8 Moderate (16)
Child 5
Before Moderate Moderate Moderate Mild Little 10 Moderate Moderate Moderate Mild Little 10 Moderate (20)
37 Mg/D Moderate Moderate Mild Mild Moderate 8 Moderate Mild Mild Mild Moderate 7 Mild (15)
Child 6
Before Severe Severe Moderate Mild Little 12 Severe Severe Moderate Mild Little 12 Severe (24)
74 Mg/D Severe Moderate Moderate Mild Moderate 10 Moderate Moderate Moderate Mild Moderate 9 Moderate (19)
111 Mg/D Moderate Moderate Mild Mild Moderate 8 Moderate Moderate Mild Mild Moderate 8 Moderate (16)
Mg/D, milligrams per day; Time Occupied/Spent, extreme (4), severe (3), moderate (2), mild (1), none (0); Interference, extreme (4), severe (3), moderate (2), mild (1), none (0); Distress, extreme (4), severe (3),
moderate (2), mild (1), none (0); Resistance, extreme (4), severe (3), moderate (2), mild (1), none (0); Degree of Control, no (4), little (3), moderate (2), much (1), complete (0); Total CY-BOCS, extreme (32–40), severe
(24–31), moderate (16–23), mild (8–15), subclinical (0–7).
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Table 5. Parents’ quotes.
Patient Lurasidone Add-on (dose) Symptom Improved
Child 1
“Since the beginning of the treatment he seems to be more
cooperative and less tied to his control issues!” (18.5 Mg/D) Aggressive behavior; Obsessive
symptoms“He now shows fewer obsessive thoughts. He also appears to
be more friendly with both his peers and adults.” (37 Mg/D)




“His behavior and compulsions at home have notably
improved.” (111 Mg/D) Obsessive symptoms
“His behavior has improved at home and he is now also less
worried about strangers and less prone to physically attack
them.” (148 Mg/D)
Aggressive behavior




“Low mood and melancholy have softened. He is still very




“No more episodes of aggression have happened since the
introduction of Lurasidone.” (74 Mg/D) Aggressive behavior
“He seems less absorbed in his thoughts.” (111 Mg/D) Obsessive symptoms
Mg/D, Milligrams per Day.
At the time of writing, no significant neuromotor or metabolic side effects had been
reported in all cases in a follow-up period ranging from a minimum of 4 months to 6 months,
supporting the stability of the observed clinical improvement.
5. Discussion
Lurasidone has high-affinity binding to D2 (antagonist), 5-HT2A (antagonist), 5-HT7
(antagonist), and 5-HT1A (partial agonist) receptors, and moderate affinity for noradrener-
gic α2C and α2A receptors, and a weak affinity for 5-HT2C receptors. It has FDA approval
for use in pediatric populations, i.e., adolescent-onset schizophrenia (13–17 years) and
bipolar depression (10–17 years). Evidence for its efficacy in children and adolescents
with autism spectrum disorder is less conclusive, as an overall improvement in the Clin-
ical Global Impression was not accompanied by an improvement in additional efficacy
measures including irritability, hyperactivity, stereotypic behavior, inappropriate speech,
lethargy/withdrawal, and obsessive-compulsive symptoms [19,20]. The available studies
also support its efficacy in reducing negative symptoms, cognitive dysfunction, and de-
pressive symptoms [4]. Furthermore, apart from a higher risk of akathisia, lurasidone has
been suggested to contain metabolic and cardiovascular side effects as compared with prior
second-generation antipsychotics, while keeping the risk of extrapyramidal symptoms
low [4]. Our findings confirm and extend previous evidence, suggesting a good safety
profile of lurasidone in the context of APP, and its effectiveness in reducing aggressive
behavior and obsessive symptoms, as well as depressive symptoms in TS.
Increasing evidence-based studies are proving the benefit of APP [21]. In line with
the very recent revision that a certain proportion of selected patients can benefit from APP
without further negative consequences [21], despite very limited and observed outside
of a clinical trial setting, evidence from our case series suggests that lurasidone add-on
therapy may be well tolerated and effective in the treatment of complex forms of TS
whose additional symptoms, namely aggressive behavior and obsessive symptoms, are
refractory to APM or the combination of single antipsychotic medications with other classes
of psychopharmacological treatments. Of course, longer follow-up evidence will be needed
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in order to assess long-term tolerability and efficacy of such polypharmacy. In addition, the
efficacy of lurasidone monotherapy as compared with placebo in patients with TS remains
to be tested. Furthermore, due to its purely clinical nature, the treatment dose was chosen
based on patient’s response, thus requiring investigation of maximum exposure and dose
levels in clinical trials. Finally, we cannot exclude a role of regression to the mean and
placebo effects in accounting for the observed change. Thus, the nature of the present data,
as well as the previous very limited and inconclusive evidence on the efficacy of lurasidone
in neurodevelopmental conditions, calls for caution in the treatment of TS with lurasidone.
6. Conclusions
While still investigational, the preliminary evidence presented here gives reason to
hope that lurasidone might be an effective option in TS, warranting further investigation
of its potential benefits in neurodevelopmental conditions.
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